Pediatricians are vaccine makers' most effective channel to address rising parental concerns and counteract falling support for routine childhood immunization schedules.
Novo Nordisk’s oral obesity treatment is set for a private-pay debut in the UK as drugmakers look to broaden GLP-1 adoption beyond injections.
Nearly four in 10 say AI helped spot multiple potential mistakes over three months, pointing to the possibility of measurable patient-safety gains.
Hospitals have been warned over weak compliance with price transparency rules, but even full compliance would do little to help patients because insurer-provided out-of-pocket cost estimates are often more useful than raw service pricing data.
Unlike broad LLMs, Talkspace's AI companion tool adds therapist intervention when its AI detects a crisis, making safety its potential edge.
It’s approved for broader UV protection, which may spur uptake and challenge the high-SPF playbook lauded by popular skincare brands.
World Cup betting frenzy will shine a spotlight on the growing consumer health risks tied to online sports gambling.
A $10.6 billion Nuvalent deal adds two near-market lung cancer drugs as its vaccine sales flatten and key HIV patent expirations approach.
But competitor data shows obesity care may widen beyond two leaders and favor whoever deliv
Paid search ad clicks in the jobs and education industry fell 13.1% YoY in Q1 2026, a stark reversal from the same category's 254% growth in Q1 2025, according to an April report from Skai.
In today’s podcast episode, we discuss what “wellness” means to Americans today, the relationship between the wellness movement and the traditional healthcare industry, and how brands and retailers are redesigning their offerings for wellness-conscious shoppers. Join Senior Director of Podcasts and host Marcus Johnson, along with Senior Analysts Rajiv Leventhal and Beth Snyder Bulik. Listen wherever you get your podcasts, or watch on YouTube or Spotify.
Free-market groups are defending direct-to-consumer drug ads. Tighter FDA claim reviews loom for pharma marketers, but a sweeping crackdown looks more and more unlikely.
Chatbots now steer patient choice, surfacing providers with rich, accurate site data.
Pharma companies back rapid reviews to speed patient access, while opponents are concerned about transparency lapses and safety trade-offs.
HealthlineAI offers pharma marketers a new way to reach high-intent patients. But it must contend with consumers going to general-purpose chatbots for health info.
Edelman study finds falling confidence in doctors, CEOs, and government as Americans consult a wider mix of health information sources.
Just 7% of US adults use AI chatbots extremely often or often for health information, while 59% never use them at all, ranking chatbots last among seven major health information sources, according to an October 2025 Pew Research Center survey.
Physicians integrate both general-purpose and clinical AI into daily workflows, increasing pressure on pharma brands to tailor drug content for the distinct requirements and outputs of each AI ecosystem.
Among ages 12 to 21, AI use for mental health rose 40% year over year, bringing chatbots further into their mainstream coping habits.
Most Americans call them addictive and blame them for obesity and diabetes, priming tougher policies and regulations.